The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care
Open accessThe DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
Purpose of Review: The global rise in obesity and type 2 diabetes mellitus (T2DM) presents significant challenges in musculoskeletal care, contributing to increased perioperative complications, impaired bone health, and compromised muscle function. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for glycemic control in T2DM, have demonstrated substantial benefits in weight reduction and metabolic regulation. The purpose of this review is to understand the musculoskeletal biologic and clinical implications of GLP-1RAs. Recent Findings: Evidence suggests that GLP-1RAs may impact musculoskeletal health through anti-inflammatory effects, bone metabolism modulation, and alterations in muscle composition. GLP-1RAs may promote osteoblastogenesis while dampening osteoclast activity to maintain bone mineral density. The result on fracture risk is unclear. Additionally, while GLP-1RAs cause lean mass loss, GLP-1RAs appear to preserve skeletal muscle, reduce fatty infiltration, and enhance fiber formation and function. Further, GLP-1Rs are present in synovial tissue and cartilage, demonstrating downregulation of inflammatory molecules and chondrocyte apoptotic pathways, though clinical studies show variable effects in the setting of osteoarthritis. Overall, the heterogeneity in findings underscores the need for further research to delineate the long-term musculoskeletal effects of GLP-1RAs. Summary: Understanding the musculoskeletal impact of GLP-1RAs is critical for optimizing their integration into orthopedic practice. This review explores the orthopedic implications of GLP-1RAs, highlighting their biologic mechanisms and clinical effects on obesity-related joint inflammation and arthropathy, bone mineral density and fracture risk, and skeletal muscle preservation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there are concerns that long-term exposure of GLP-1 RAs at supratherapeutic or maximum approved maintenance doses may impair muscle cell differentiation and potentially contribute to the development of sarcopenia, despite their potential to improve muscle metabolism and quality [83, 88].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“physical performance and functional outcomes are generally preserved or improved in most studies, particularly when resistance training is maintained”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [71]
Experimental — accuracy not yet measuredIn the citing paper
“GLP-1RAs promote glucose uptake in the skeletal muscle by increasing microvascular blood flow and tissue perfusion and inhibit muscle catabolism via the AMP-activated protein kinase pathway [39, 77, 83].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Recent high quality randomized controlled trials (RCTs) have highlighted the clinical benefits of GLP-1RAs, namely improved glycemic control, cardiovascular risk reduction, and weight management [73–76].”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“Up to 40% of overall weight loss with semaglutide, and up to 25% with tirzepatide, is attributed to lean body mass, which raises concerns that the drug therapy may hold a negative effect upon skeletal muscle mass and function [10, 47].”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“Recent high quality randomized controlled trials (RCTs) have highlighted the clinical benefits of GLP-1RAs, namely improved glycemic control, cardiovascular risk reduction, and weight management [73–76].”
ANDERSON, J. J., & FELSON, D. T. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114939 · Cited by 892
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“Though initially developed for T2DM management, large trials such as Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) [9 ] and Semaglutide Treatment Effect in People with Obesity (STEP) [10] have consistently shown substantial decreases in body weight and optimization…”
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“Further, GLP-1RA act on thyroid C-cells, increasing calcitonin levels, thereby promoting osteoprotegin expression and inhibiting receptor activator of nuclear factor-κB ligand (RANKL), effectively reducing osteoclast-mediated bone resorption [34, 39, 40].”
Cited by
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 53
Sawicka‐Gutaj, N., Gruszczyński, D., Nijakowski, K., Derwich-Rudowicz, A., Krenz, M., Kumar, A. A., Lu, P.-Y., & Ruchała, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02088-1 · Cited by 24
Țica, O., Romanul, I. M., Ciavoi, G., Pantea, V. A., Scrobotă, I., Șipoș, L. R., Daina, C. M., & Ţică, O. (2025) · Biomedicines · doi:10.3390/biomedicines13092309 · Cited by 22
Qaisar, R., Khan, I. U., Rehman, A. U., Iqbal, M. S., Ahmad, F., & Karim, A. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70253 · Cited by 20
Šantić, R., Martinovic, L., Pavlović, N., Rušić, D., Kumrić, M., Martinović, D., Kurir, T. T., & Božić, J. (2026) · Metabolites · doi:10.3390/metabo16060364 · Cited by 11
Metadata
- Authors
- Gatto, A., Liu, K., Milan, N., & Wong, S.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Gatto, Andrew
- Venue
- Current Reviews in Musculoskeletal Medicine
- Published
- 2025-05-15
- Volume
- 18
- Issue
- 10
- Pages
- 469-480
- ISSN
- 1935-973X (ISSN-L)
- 1935-9748
- PMC
- PMC12325148
- OpenAlex
- W4410414424
- Cited by
- 55
- References
- 107
- Citations by year
- 2026: 46 · 2025: 9
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Current Reviews in Musculoskeletal Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Keywords
- GLP-1 receptor agonists, musculoskeletal health, type 2 diabetes, obesity, bone mineral density, osteoblastogenesis, osteoclast activity, fracture risk, lean mass loss, muscle fat infiltration, osteoarthritis, synovium, cartilage, chondrocyte apoptosis, joint inflammation, orthopedic care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. https://app.cochat.ai/papers/10.1007/s12178-025-09978-3
- The paper
- Gatto, A., Liu, K., Milan, N., & Wong, S. (2025). The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. Current Reviews in Musculoskeletal Medicine. https://doi.org/10.1007/s12178-025-09978-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.